Literature DB >> 28209863

CRISPR, surrogate licensing, and scientific discovery.

Jorge L Contreras1, Jacob S Sherkow2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28209863     DOI： 10.1126/science.aal4222

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  6 in total

1.  The ethics of access to patented biotech research tools from universities and other research institutions.

Authors:  Knut J Egelie; Sabina P Strand; Berit Johansen; Bjørn K Myskja
Journal:  Nat Biotechnol       Date:  2018-06-06       Impact factor: 54.908

2.  CRISPR, Patents, and the Public Health.

Authors:  Jacob S Sherkow
Journal:  Yale J Biol Med       Date:  2017-12-19

3.  Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic.

Authors:  Dianne Nicol; Lisa Eckstein; Michael Morrison; Jacob S Sherkow; Margaret Otlowski; Tess Whitton; Tania Bubela; Kathryn P Burdon; Don Chalmers; Sarah Chan; Jac Charlesworth; Christine Critchley; Merlin Crossley; Sheryl de Lacey; Joanne L Dickinson; Alex W Hewitt; Joanne Kamens; Kazuto Kato; Erika Kleiderman; Satoshi Kodama; John Liddicoat; David A Mackey; Ainsley J Newson; Jane Nielsen; Jennifer K Wagner; Rebekah E McWhirter
Journal:  Genome Med       Date:  2017-09-25       Impact factor: 11.117

4.  Mind the gaps! Towards an ethical framework for genome editing.

Authors:  Matthias Braun; Peter Dabrock
Journal:  EMBO Rep       Date:  2017-12-27       Impact factor: 8.807

Review 5.  Opioid Addiction, Genetic Susceptibility, and Medical Treatments: A Review.

Authors:  Shao-Cheng Wang; Yuan-Chuan Chen; Chun-Hung Lee; Ching-Ming Cheng
Journal:  Int J Mol Sci       Date:  2019-09-02       Impact factor: 5.923

6.  Governance Choices of Genome Editing Patents.

Authors:  Naomi Scheinerman; Jacob S Sherkow
Journal:  Front Polit Sci       Date:  2021-09-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.